Trust Company of Vermont’s Tempest Therapeutics TPST Stock Holding History

Trust Company of Vermont’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Hold	0	–	-$1K	–	1037
2019 Q2	–	Hold	0	–	–	–	1007
2019 Q1	–	Hold	0	–	–	–	959
2018 Q4	–	Sell	-1	Closed	-$2.06K	–	969
2018 Q3	$1K	Hold	1	–	–	﹤0.01%	1035
2018 Q2	$1K	Hold	1	–	–	﹤0.01%	1051
2018 Q1	$1K	Hold	1	–	–	﹤0.01%	945
2017 Q4	$2K	Hold	1	–	–	﹤0.01%	928
2017 Q3	$2K	Hold	1	–	–	﹤0.01%	895
2017 Q2	$2K	Hold	1	–	–	﹤0.01%	936
2017 Q1	$3K	Hold	1	–	–	﹤0.01%	822
2016 Q4	$2K	Hold	1	–	–	﹤0.01%	847
2016 Q3	$10K	Hold	1	–	–	﹤0.01%	674
2016 Q2	$8K	Buy	+1	New	+$22.8K	﹤0.01%	640

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.36B AUM 21.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Trust Company of Vermont's TPST Position: Q3 2019 in Review

Trust Company of Vermont held its Tempest Therapeutics (TPST) position steady in Q3 2019 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1037.

Trust Company of Vermont first reported a position in TPST in Q2 2016 and has held it in 10 quarters since. The position peaked at $10K in Q3 2016. 41 funds tracked by Wall St. Rank hold TPST as of Q3 2019.

Trust Company of Vermont held 0 shares of Tempest Therapeutics worth $0 as of Q3 2019.
Trust Company of Vermont left its Tempest Therapeutics share count unchanged in Q3 2019.
Tempest Therapeutics made up ﹤0.01% of Trust Company of Vermont's portfolio in Q3 2019, its #1037 holding.
Trust Company of Vermont first reported a position in Tempest Therapeutics in Q2 2016 and has held it in 10 quarters since.
Trust Company of Vermont's Tempest Therapeutics position peaked at $10K in Q3 2016.
41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2019.

Based on Trust Company of Vermont's 13F filing for Q3 2019, filed 24 Oct 2019.